Bard Port Catheter Lawsuit Evidence: Device Records, Fracture Science, and MDL 3081

What an implanted port is—and what this MDL covers

An implanted venous access port places a reservoir under the skin and connects it to a catheter terminating in a central vein. It can support chemotherapy, fluids, nutrition, blood products, blood draws, and power injection depending on the model. The JPML created MDL 3081 in August 2023 for federal actions sharing allegations about Bard implanted port-catheter products. Plaintiffs allege that catheter materials can degrade, fracture, migrate, or contribute to other complications; Bard disputes defect and causation.

Product scope matters. A chest PowerPort, arm port, PowerPICC, and midline catheter are not interchangeable devices. The 2025-2026 FDA recall involving certain Bard PowerPICC catheters concerned peripherally inserted central catheters and material-fatigue leaks; it should not be presented as a recall of every implanted PowerPort in MDL 3081. The implant card, operative note, UDI, catalog number, and lot are the starting point for knowing which evidence applies.

Known complications do not answer the defect question

FDA 510(k) records and manufacturer labeling for Bard PowerPort systems list possible complications such as catheter fracture, catheter embolism, migration, occlusion, infection, thrombosis, extravasation, vascular erosion, and device dislodgement. Medical literature likewise documents rare fracture and migration events with totally implantable venous access systems from multiple manufacturers. Recognition of a complication establishes that an event is clinically possible; it does not identify why a particular catheter failed.

Potential explanations can include pinch-off between anatomical structures, catheter compression or kinking, connection problems, placement technique, repeated access, mechanical stress, dwell time, infection, thrombosis, patient anatomy, or material behavior. Plaintiffs in MDL 3081 advance product-specific degradation theories, while defendants may argue alternative mechanisms and accepted risks. Reliable analysis matches the fracture surface, location, imaging, procedure history, and material to the proposed mechanism.

What FDA recall records can and cannot prove

FDA's recall database shows specific Bard port recalls, including a 2019 action involving selected lots packaged with an incorrect tunneler component. That recall addressed identified product codes and lots and a risk of prolonging surgery. It did not announce that all PowerPort catheters were defective or confirm the material-degradation allegations in MDL 3081. Recall scope, reason, lot, and status must be quoted exactly.

The separate PowerPICC action announced in 2025 and classified by FDA as Class I in January 2026 involved certain 4 French single-lumen PICCs and an increase in material-fatigue leaks associated with a catheter-resin issue. FDA reported 10 serious injuries in that communication. It is useful evidence about those recalled PICCs, not automatic evidence about an implanted port model. Similar brand language is not a substitute for matching a UDI or catalog number.

Where MDL 3081 stood in 2026

The District of Arizona developed common discovery, expert proceedings, and a bellwether sequence. An August 2025 case-management order listed trials for Robert Cook beginning March 2, 2026, Wanda Miller beginning April 27, and May Lattanzio beginning July 7. A March 20, 2026 order addressed final-pretrial details for Cook. These dated orders show that the litigation reached trial testing rather than remaining at initial pleading stage.

A planned trial can settle, continue, end in a verdict, or change by later order, so the schedule alone should not be reported as an outcome. Each bellwether turns on a selected product, medical history, experts, and alleged failure. Even a completed verdict would inform the parties without binding thousands of other plaintiffs. Official sources reviewed through July 10, 2026 do not publish a universal settlement matrix, claims deadline, or guaranteed value.

The evidence file that can distinguish a claim

A complete file includes the implant card and UDI, placement operative report, access and flushing history, imaging before and after symptoms, notes documenting resistance or inability to draw blood, infection and culture records, thrombosis studies, removal or retrieval operative report, photographs, and pathology or materials analysis. Imaging can show migration or fracture location; an explant can permit examination if preserved through appropriate medical and legal channels.

Symptoms such as pain, swelling, infusion difficulty, fever, or shortness of breath require medical evaluation, not web diagnosis. FDA advises reporting device problems through MedWatch, but a report does not determine legal causation. Patients should not request elective explant solely for litigation. Legal review must also address manufacturer identity, state-law timing, prior conditions, alternative mechanisms, and whether the exact model falls within pleaded MDL allegations.

Reader questions

Frequently asked questions